HC Wainwright Comments on Aemetis, Inc.’s Q1 2023 Earnings (NASDAQ:AMTX)

Aemetis, Inc. (NASDAQ:AMTX – Get Rating) – Equities research analysts at HC Wainwright issued their Q1 2023 earnings per share (EPS) estimates for Aemetis in a research note issued on Monday, March 13th. HC Wainwright analyst A. Dayal anticipates that the specialty chemicals company will post earnings of ($0.31) per share for the quarter. The consensus estimate for Aemetis’ current full-year earnings is ($0.57) per share. HC Wainwright also issued estimates for Aemetis’ FY2027 earnings at $3.97 EPS.

A number of other research firms have also recently commented on AMTX. Truist Financial cut their target price on Aemetis from $9.00 to $5.00 and set a “hold” rating on the stock in a research report on Wednesday, February 1st. Ascendiant Capital Markets dropped their price target on Aemetis to $26.00 in a research report on Wednesday, November 16th. Piper Sandler initiated coverage on Aemetis in a research report on Monday, February 27th. They issued an “underweight” rating and a $3.00 price target on the stock. Finally, UBS Group initiated coverage on Aemetis in a research report on Tuesday, December 13th. They issued a “neutral” rating and a $4.25 price target on the stock. Two equities research analysts have rated the stock with a sell rating, two have assigned a hold rating and two have assigned a buy rating to the company’s stock. According to MarketBeat.com, the stock currently has an average rating of “Hold” and a consensus price target of $13.05.

Aemetis Stock Performance

AMTX opened at $2.76 on Tuesday. The business’s 50-day simple moving average is $4.07 and its 200-day simple moving average is $5.51. Aemetis has a one year low of $2.51 and a one year high of $13.78. The stock has a market capitalization of $101.15 million, a P/E ratio of -0.87 and a beta of 0.87.

Institutional Investors Weigh In On Aemetis

Institutional investors have recently added to or reduced their stakes in the business. Barclays PLC boosted its holdings in Aemetis by 542.0% in the 4th quarter. Barclays PLC now owns 8,031 shares of the specialty chemicals company’s stock valued at $32,000 after purchasing an additional 6,780 shares in the last quarter. Tower Research Capital LLC TRC boosted its holdings in Aemetis by 173.7% in the 3rd quarter. Tower Research Capital LLC TRC now owns 5,586 shares of the specialty chemicals company’s stock valued at $34,000 after purchasing an additional 3,545 shares in the last quarter. BNP Paribas Arbitrage SA boosted its holdings in Aemetis by 105.6% in the 2nd quarter. BNP Paribas Arbitrage SA now owns 9,517 shares of the specialty chemicals company’s stock valued at $47,000 after purchasing an additional 4,887 shares in the last quarter. The Manufacturers Life Insurance Company purchased a new stake in Aemetis in the 4th quarter valued at approximately $49,000. Finally, SG Americas Securities LLC purchased a new stake in Aemetis in the 2nd quarter valued at approximately $54,000. Hedge funds and other institutional investors own 50.72% of the company’s stock.

Aemetis Company Profile

(Get Rating)

Aemetis, Inc is a renewable fuels and biochemical company, which engages in the acquisition, development, and commercialization of technologies that replace traditional petroleum-based products. It operates through the North America and India geographical segments. The North America segment manages Keyes Plant in California, the cellulosic ethanol facility in Riverbank, the cluster of biogas digesters on dairies near Keyes, California, the Goodland Plant, Kansas and the research and development facility in Minnesota.